Related Experiment Videos
Cascade genetic screening for familial hypercholesterolemia
1Medical Genetics Laboratory, Department of Medical Genetics, Rikshospitalet, Oslo, Norway. trond.leren@rikshospitaelet.no
Clinical Genetics
|November 4, 2004
Summary
Cascade genetic screening for familial hypercholesterolemia (FH) effectively identifies affected individuals and is cost-effective. Implementing national FH screening programs integrated into routine healthcare ensures significant health benefits.
Area of Science:
- Genetics
- Cardiology
- Public Health
Background:
- Familial hypercholesterolemia (FH) is an inherited condition causing high LDL cholesterol and premature heart disease.
- Despite available treatments, FH diagnosis rates are low (approx. 20%), with inadequate treatment for most patients.
- The low-density lipoprotein receptor gene mutation is the primary cause of FH.
Purpose of the Study:
- To review the organization and effectiveness of cascade genetic screening for FH.
- To assess the cost-efficiency, health benefits, and potential adverse effects of FH screening programs.
- To evaluate the inclusion of children in FH screening initiatives.
Main Methods:
- Review of existing literature on familial hypercholesterolemia and cascade genetic screening programs.
- Analysis of cost-efficiency, health outcomes, and psychosocial impacts.
- Focus on the practical organization of screening programs.
Main Results:
- Cascade genetic screening is the most cost-effective strategy for diagnosing FH.
- FH screening programs demonstrate significant health benefits and are cost-effective.
- No significant psychological or social damage was associated with cascade genetic screening.
Conclusions:
- Cascade genetic screening for FH is beneficial and cost-effective.
- National FH screening programs should be integrated into standard healthcare.
- Early diagnosis and treatment of FH through screening can prevent premature coronary heart disease.